Digital Health Innovators
Featured Digital Health Innovators
All Digital Health Innovators
3-D Medical Animation
Digital Health Innovators
Founded in 1991, Houston-based Blausen Medical Communications, Inc., is the developer, owner and licensor of the world's largest library of 3D medical animations. Known for their high standard of excellence in scientific and medical accuracy, Blausen creates masterpieces that explain difficult concepts with exceptional clarity. Blausen Medical's extensive library content is available for multiple platforms. The award-winning animation library is now viewed in every country in the world and has been translated into over 21 languages. The company and its products have received over 30 honors, including the 2013 Platinum Award for Best Interactive Site; and the Gold Award for Best Mobile Communications in eHealthcare Leadership. Blausen Medical has also been honored with numerous Web Health Awards, and with an ABBY Award from the Adaptive Business Leaders Organization for developing innovations that reduce the cost of quality healthcare. The Blausen Human Atlas is currently licensed and distributed via web, smart phone, and tablet app platforms. Most recently, the Company launched the Blausen.com search engine in conjunction with the Blausen It web browser extension. Bruce has over 20 years of experience in the field of new media and medical animation and has created work for a variety of clients including Merck, Pfizer, Dateline NBC, Prentice Hall Publishing, Discovery Health, GE Medical and Kodak. A pioneer in Internet marketing and communications, Bruce has spearheaded the development of numerous interactive web sites, videos and portals for a myriad of scientific and business clients. Bruce founded Blausen Medical Communications in 1991 and has created the country's largest library of 3D medical animation and graphic content. A medical illustrator and media visionary, Bruce holds a Masters degree from the Johns Hopkins University School of Medicine and two undergraduate degrees in Biology and Art from The Pennsylvania State University. Address: 10111 Richmond Avenue, Ste 525, Houston Texas 77042 Call: 800.999.6173 Fax: 713.334.6822 [email protected] Blausen Medical Communications's Social Media Source: https://blausen.com/
Accolade
Digital Health Innovators
This is the future of healthcare, and the future is now. What’s next in employee experience? Exceptional healthcare delivered by humans. Not bots. With Accolade, your people and their families are treated like individuals. We provide access to quality primary care, mental health support and expert medical opinions all backed by a team of clinical and benefits specialists. It’s an experience your people will love. Those who work at Accolade share a vision: every person living their healthiest life. In support of that vision, we want to transform how your employees use their benefits and healthcare resources. Whether you’re a small team or a large organization, we’re here to make personalized healthcare accessible and to drastically improve the experience your employees have with healthcare and benefits. With compassionate advisers, clinical expertise, and intelligent technology, Accolade brings employees and their families trusted, personalized support for their health and benefits questions, needs and experiences. We are equally a trusted partner for employers as they foster healthy populations and effective benefits programs. Accolade solutions are designed with next-generation technology that generates millions of data-driven insights from hundreds of sources to help each person live their healthiest life. With artificial intelligence at the core of our human support, we anticipate a person’s needs, engage them in trusted ways, and guide them to the specific benefits and ca re options that can help them most, when they need them most, in the context of their full life. We guide each individual to resources they didn’t even know they had, putting them on the best path toward physical, emotional, and financial health and well-being.The Accolade journey starts with one message, one call, one point of contact. It starts when people simply ask Accolade. Source: https://www.accolade.com/
AHA - Center for Health Technology & Innovation
Digital Health Innovators
As part of the American Heart Association, the Center collaborates with innovative companies to connect entrepreneurs, providers, researchers and payers to accelerate novel health outcomes. To develop and deliver evidence-based, scalable, digital health solutions across the health continuum through innovative health-tech relationships. We imagine a world where these intelligent, digital health solutions and treatments provide affordable healthcare access for patients and their families. To accomplish this, the Center often plays two roles: that of convener, bringing parties together to solve a problem, and that of a strategic collaborator, lending our expertise to develop products and/or solutions. To help bring this vision to life, the Center has created an Innovators’ Network, an industry cohort that serves to connect digital health entrepreneurs, providers, clinical researchers, pharma and payers. For more: Innovators’ Network The Center’s Intelligent Health Solutions include access to the American Heart Association’s digital CarePlans, which help users better understand and manage their conditions. These branded, science based, CarePlans span heart health topics and are delivered in a variety of digital formats, including videos, assessments and challenges. Our annual meeting brings together top healthcare providers and researchers, health technology experts, industry thought leaders and entrepreneurs from the world’s most renowned companies and institutions. The program is specifically designed to increase collaboration between the members of this influential group, encouraging discussion about innovative health solutions, while sharing ideas and experiences. Patrick Wayte, MBA SVP, Center for Health Technology and Innovation Patrick Dunn, PhD, MS, MBA Program Director, Center for Health Technology and Innovation Darcy BarrettExecutive Assistant, Center for Health Technology and Innovation The six cardiologists who founded the American Heart Association in 1924 would be amazed. From humble beginnings, the AHA has grown into the nation’s oldest and largest voluntary organization dedicated to fighting heart disease and stroke. A shared focus on cardiovascular health unites our more than 40 million volunteers and supporters as well as our more than 2,800 employees. Learn more about our impact over time . Heart disease is the No. 1 killer worldwide, and stroke ranks second globally. Even when those conditions don’t result in death, they cause disability and diminish quality of life. We want to see a world free of cardiovascular diseases and stroke. Our size and scope let us have real impact. The AHA has invested more than $4.8 billion in research, making us the largest not-for-profit funding source for cardiovascular and cerebrovascular disease research next to the federal government. Learn more about our life-changing funded research breakthroughs . Source: https://ahahealthtech.org/about-us/
AiZtech Labs
Digital Health Innovators
AiZtech is developing a new class of digital health technology called "Selfie Diagnostics™". This novel modality can screen various disease states and cardiac status using a smartphone camera to scan facial and ocular topography. This AI-powered secure technology was first be deployed as a COVID-19 screening test. Everyone This novel COVID-19 test is as simple as taking a selfie on a smartphone. Yes, that simple! So everyone can do a self-test and get the results in 30 seconds. Everyday As it is as simple as a selfie, this non-invasive test can be done every day. Rapid testing is key for controlling COVID-19 infections when done regularly. This technology makes it a daily habit. Everywhere This non-contact test is run 100% online, making it accessible everywhere. It does not require a healthcare professional for administration it is not limited by the traditional supply chain. - The most prevalent ocular surface manifestation found within COVID-19 samples is conjunctivitis (Inomata et al., 2020). - Various forms have been found including follicular conjunctivitis (Aggarwal, et al., 2020) keratoconjunctivitis (Cheema et al., 2020), bilateral (Salducci et al., 2020), and unilateral (Sindhuja et al., 2020; Guo et al., 2020). - Research shows that pathological ocular surface changes occur at the onset of COVID-19 infection at the cellular and tissue level even if ocular manifestations remain at a subclinical level. - These ocular surface manifestations can be detectible by AiZtech's deep learning engine and used in screening and surveillance testing for COVID-19 infections. This novel modality compliment is to compliment available tools to bend the curve of infections and enable everyone to live a life unlimited by a pandemic. Here is a summary of key findings on how the eye plays a key role in the detection of active COVID-19 infection up to 7 days before pulmonary symptoms occur. - SAR-COV-2 virus penetrates human cells through ACE2 receptors among others. ACE2 receptors are commonly found at cells lining the lungs nasopharynx, and nasolacrimal duct, (Bourgonje et al., 2020). - Zhou et al. showed ACE2 expression on the ocular surface, predominantly on the superficial conjunctival and corneal epithelial surfaces. With this evidence, the eye can serve as a portal for viral entry and/or inoculation, (Zhou et al., 2020). - Other studies stated that ocular manifestations in the form of local, transient vasculitis cannot be excluded because of the high vascularity of the conjunctiva and the expression of ACE2 on the surface of endothelial cells (Aiello et al., 2020). Source: https://www.aiztechlabs.com/
AliveCor
Digital Health Innovators
AliveCor is the leading FDA-cleared mobile heart solution that delivers intelligent, highly-personalized information about the heart to clinicians and patients anytime, anywhere. KardiaMobile is the most clinically-validated personal EKG solution in the world. KardiaMobile can detect atrial fibrillation, bradycardia, tachycardia, and normal heart rhythm in just 30 seconds. Kardia is the first AI-enabled platform to aid patients and clinicians in the early detection of AFib. Arrhythmias don’t wait for the doctor’s office, so we created a portable, durable personal EKG that goes anywhere you go. KardiaMobile Card is as thin and light as a credit card, fits perfectly in your wallet, and records an accurate, medical-grade EKG in seconds. KardiaMobile Card also includes an exclusive KardiaCare membership, so you can better manage and understand your heart health on the go. Thin and light as a credit card. KardiaMobile Card is the size and weight of a standard credit card, so you can store it in your wallet and have it on you at all times. Bluetooth enabled. KardiaMobile Card uses Bluetooth technology to connect to your phone and record medical-grade EKGs. No WiFi required, so you can record your EKG from anywhere. Six arrhythmia detections. Accurately detect AFib, Bradycardia, Tachycardia, PVCs, Sinus Rhythm with SVE, and Sinus Rhythm with Wide QRS. That’s more detections than any other personal EKG. Data you can trust. Kardia technology is clinically validated, FDA-cleared, and recommended by doctors worldwide. Durability you can rely on. KardiaMobile Card has been tested to withstand wear and tear. We’ve made sure to water test, temperature test, and sit test so you can use KardiaMobile Card anywhere without worry. Includes device and KardiaCare membership. You’ll get KardiaMobile Card plus a KardiaCare membership all in one, which gives you enhanced EKG analysis and further information about your heart health. Compatible with smartphones. Works with most smartphones and tablets. See our compatible devices here . KardiaMobile Card is not tested or recommended for use with pacemakers and ICDs. KardiaMobile Card does not check for heart attack. KardiaMobile Card includes KardiaCare, our one-of-a-kind heart health membership. KardiaCare provides you with exclusive features that will help you better understand and manage your heart health. Members also have access to our advanced algorithm, which means everytime you take an EKG it will be analyzed with our most sophisticated, accurate technology. Enjoy these features with KardiaCare: Unlimited EKGs Advanced Determinations Cardiologist EKG Reviews Heart Health Report Unlimited Cloud Storage and Security Automatic EKG Sharing Weight and blood pressure monitoring Medication Tracking Device Replacement Source: https://www.kardia.com/
Aptus Life - Elderly Parent Care
Digital Health Innovators
Aptus Life gives children caring for elderly parents Peace of Mind by connecting and aggregating all sources of data from providers, caretakers, remote monitoring devices and individuals. Aggregated data enables informed parent care decisions. Aptus Life installs three levels of remote monitoring device technology, depending on the severity of the conditions being monitored: Level 1 - Parents are successfully navigating life - children concerned about falls, eating correctly, unusual house events. Level 2 - Children are concerned about mental and/or physical decline - requires 24/7 monitoring. Level 3 - Parents are housebound with diagnosed mental disease and/or physical disibilities. - requires parent and caregiver monitoring 24/7 As chronic diseases continue to be a burden on society, technology is being used more and more. About half of all adults suffer from one or more chronic diseases, which account for seven of 10 deaths and 86% of U.S. health-care costs. But preventing and treating such ailments requires time that doctors don’t have in brief office visits, and a degree of daily self-management that many patients have been unable to achieve. They often become overwhelmed by the demands of their daily regimens, slip back into poor health habits, fail to take their medications correctly—and end up in the emergency room. Technology is offering a new fix for one of the most confounding health-care challenges: getting patients with chronic disease to take better care of themselves. How many patients can your solution serve? Unlimited. There is no limit to the number of patients Aptus can manage. It is easy to scale up and down. The provider will have access to one portal that they can brand and customize, as needed, to quickly see stats for all the patients in one place. What’s the cost of your solution and the ROI? Our cost averages to be $120 a month per patient. The revenue ROI back to the provider is roughly $300 per patient. The larger the patient population, the higher the reimbursement amount. The amount received back is immediate for the current patient population of any size. Providers get reimbursed directly from CMS through our billing and reconciliation engine. For the patient, they are only billed their regular copay. What are the onboarding requirements for new practices? Onboarding is simple. Our team will need to know your desired timing and establish a point of contact for setup and ongoing reporting. We ask what financial tools you use for faster integrations. We also need to know EMR and data integrations. Together, we go over compliance and patient privacy. Can your solution be integrated with our organization’s EHR? Yes. We are device and system agnostic. Our team truly tries to make this as simple as possible for the provider. Aptus is here to enhance your daily operations, not to replace anything that you are currently doing. What insights can physicians get from Aptus? Physicians get real-time access to all of the patient biometrics, which is automatically sent for provider and family. Typically, physicians will not receive data from the device unless the patient is in the office. With Aptus, they can receive timely alerts when something is out of the medical norm. How does your solution help the provider to improve patient outcomes? Since we are working together with the provider we are able to monitor all of their vitals in real-time alleviating a lot of the guesswork and keeping them in the home longer and out of the hospital. A provider can easily access any patient's account and specific documents and history associated with that account via keywords. It is a one-portal view of your whole patient population. Does your solution include medical devices? We have a list of over 150 devices that can be used that are both Bluetooth and cellular. Depending on the volume, we can look at customized devices and add them to our platform. We can provide the devices or you use what was purchased by the provider. Who ships the devices to patients’ homes? Our team does all of the medical device fulfillment. We can ship devices directly to the provider or the patient. How do you secure patient data? All data is secure. We are 100% HIPAA compliant, and all data is encrypted to protect the patient. Does Aptus replace my home health care team? Aptus does not replace your home health care team but improves efficiency and profitability by notifying you when and where somebody needs you eliminating unnecessary work and travel. Source: https://www.aptus.life/
Aspen Insights
Digital Health Innovators
Demonstrating what is possible with applied data science, artificial intelligence, and machine learning for advancing healthcare and human performance. Headquartered in Fort Worth, Texas, Aspen Insights is a data science and artificial intelligence firm principally engaged in the research, design, development, and integration of healthcare analytics systems, products, and services. To define the state of the art in applied data science, artificial intelligence, and machine learning for health and human performance To bring innovative medical treatment to patients faster by streamlining the clinical research recruiting process We are dedicated to separating marketing hype from reality by focusing on results and generating real value and durable competitive advantage for our clients. We value diversity: whether it is our human capital, our deep learning frameworks, our programming languages, or the domain in which we apply our technology; our diversity is our strength. We perform with excellence. Aspen Forge provides a means to dramatically increase clinical trial enrollment rates by using sophisticated machine learning algorithms and electronic health records, which enables accurate enrollment feasibility analysis, optimal candidate identification, and a streamlined recruitment workflow. Aspen Forge features intuitive solutions to assess your access to patients that qualify for a given clinical trial. An easy to use search form allowing the user to input key inclusion and exclusion criteria associated to a trial. A monte carlo simulation with detailed outputs of likely arrival and enrollment projections, considering interest and qualification conversion rates. A means to dissect a trial matching patient population by age, ethnicity, BMI, blood pressure, and more. Aspen Forge alleviates the need for performing time-consuming, tedious searches through your EHR to identify the right patient for clinical trial enrollment. Instantly be presented with a ranked list of highly probable candidates matching a clinical trial of interest. View a comprehensive reason for why each patient may qualify for the trial based on their medical record content. Aspen Forge includes a flexible workflow solution, complete with patient match review and triage, staff approval queues, a centralized recruitment framework, and CTMS integration Uses Aspen tools to identify trial candidates and perform feasibility studies Reviews and approves potential subjects from match lists. Engages patient and coordinates their clinical trial journey. Source: https://www.aspeninsights.com/
Aventyn
Digital Health Innovators
Aventyn is an innovative, award winning digital therapeutics company connecting patients and clinicians for precision chronic disease management. Vitalbeat connected wearables enable first-in-class, evidenced intelligent digital therapeutic actionable biomarkers for heart failure and co-morbidities. Vitalbeat clinically-validated solutions offer personalized, predictive health risk assessment and immersive virtual care delivery platform with integrated long haul disease management for improved patient health outcomes at lower cost and better quality of life. Aventyn is a San Diego, California based Digital Health company committed to developing and delivering innovative, clinical evidenced secure Connected Information Processing solutions for the healthcare enterprise. Founded in 2004, Aventyn is a privately held venture. Our headquarters is in Carlsbad, CA with offices in Bangalore, India; Stockholm, Sweden and London, United Kingdom with representation in the UAE. Aventyn's proven leadership team and advisory board have considerable global technology, clinical and academic research experience in the field of health IT, security, wireless, enterprise software, embedded, semiconductors and most importantly, delivering leading-edge health care and health information technology solutions. Aventyn brings about standards-based innovative solutions to the healthcare marketplace that enable interoperable electronic health information sharing, connects wearable, mobile medical devices and IoT assets that significantly improve business critical resource management. Aventyn’s connected modular solution enables secure, seamless sharing of interoperable clinical information tailored to a patient-centric model for improved patient outcomes, rapid ROI, reduced hospital visits achieved at lower costs. Solution Deployment CLIP®Care and Vitalbeat® evidenced solutions from Aventyn are designed for deployment at Healthcare Providers, Payors, Medical Device Manufacturers, Wireless Operators, Pharmaceutical Companies and Healthcare System Integrators. Our journey started with the vision to address the U.S. national burden of healthcare cost, patient safety and health care when President George Bush signed an executive order in 2004 creating the position of the Office of the National Coordinator for Health Information Technology ( ONCHIT ) within the Department of Health and Human Services. ONCHIT issued a public Request for Information regarding a National Health Information Network. The NHIN initiative outlines the nationwide implementation of interoperable health information technology across the industry. The initiative recommends the need for using identification technology to meet key goals such as portable electronic patient records, interoperable clinical information and medical asset tracking to increase patient safety to name a few. Aventyn, Inc. supports the NHIN initiative and submitted a response to the public RFI ( Download Aventyn Response ). A complete report representing responses from a cross-section of industry stakeholders is available here at HHS. Message from ETSI ETSI, the European Telecommunications Standards Institute, is Europe's officially-recognized standardization body for Information and Communication Technologies (ICT), including telecommunications and broadcasting. An independent organization based in Sophia Antipolis, France, ETSI unites almost 700 members from 55 countries inside and outside Europe, including manufacturers, network operators, administrations, service providers, research bodies and users – in fact, all the key players in the ICT arena. As many of these members are active globally, ETSI's focus extends well beyond Europe. The institute plays a major role in developing a wide range of specifications as Europe's contribution to world-wide ICT standardization. ETSI's prime objective is to support global harmonization by providing a forum in which all the key players can contribute actively. In addition, it has specific responsibilities within Europe, notably in support of European regulation and legislation, and is officially recognized by the European Commission and the EFTA Secretariat. www.etsi.org Navin Govind is founder and CEO of Aventyn, Inc., an award winning Carlsbad, CA based digital health company. Navin was founder and CEO of Antargata a privately funded digital security venture. Previously, Navin was a founding team member at Tarari, Inc.; a venture backed privately held company from San Diego that was later acquired by LSI Logic. Navin started his career in the nineties and spent a decade at Intel Corporation contributing to the development of several multi-billion dollar winning global strategies for the adoption of new technology, architecture and products. Navin has authored several original papers in peer reviewed journals and holds issued and pending patents. He has served as speaker and advisor at numerous health and technology industry panels, profiled in Kauffman Foundation Entrepreneurs in Digital Medicine, MIT Technology Review, US Chamber of Commerce Global IP CONNECT voices on Innovation Lifecycle, TiE Silicon India and involved in digital health standards initiatives at TIA, HIMSS, IEEE and ETSI amongst others. Navin participates in the annual business leader’s delegation at White House briefings where more recently President Barack Obama addressed business leaders on federal legislation and policy matters. In addition to meeting with a host of congressional leaders and lawmakers, including former Chairs of the House Budget Committee and Directors of the Office of Management and Budget where he talked about critical issues ranging from contracting to immigration, innovation and healthcare. He serves as advisor to TIA, VitaNlink, Health Technology Forum, Southern California Biotechnology Center advisory council and is the executive chairman for b-eCare Connected Health initiatives. Currently, with the launch of Aventyn’s Global Health Innovation Ecosystem and continued success as sponsor of its unique international, multi-center clinical evidence studies for management of chronic conditions; Navin passionately leads Aventyn in the commercialization of its novel digital health solutions fostering innovation in mobile connected medical technologies. Dr. Vijay is Board Certified in Internal Medicine, Cardiology and Clinical Lipidology. He is a Fellow of the American College of Cardiology, a Fellow of the American College of Physicians, and a Fellow of the American College of Chest Physicians and is the immediate past President of the American College of Cardiology. Dr. Vijay served as the past President of the Cardiorenal Society of America and President Elect for the South Westregion of the National Lipid Association, with special interests in: Heart failure treatment, Non-invasive cardiology, Nuclear cardiology, Diabetes, Complex Lipid Disorders. Dr. Kris Vijay is the Medical Director of the Institute of Congestive Heart Failure at Abrazo Arizona Heart Hospital and Heart Institute in Phoenix. He is a Clinical Professor of Medicine at University of Arizona and Midwestern University. Dr. Brodin is a cardiologist and former dean at KTH, The Royal Institute of Technology in Stockholm, a frequent speaker, editor and board member of private and academic entities. Dr. Brodin earned his medical doctorate and a PhD from the Karolinska Institute, Stockholm, Sweden. He has over a hundred scientific publications and an equal number of medical abstracts and conference reports credited to his name. Additionally, Dr. Brodin is an acknowledged expert in the field of cardiac imaging techniques, namely tissue Doppler echocardiography with several books, publications and awarded patents. He has been singularly responsible for proposing and developing international clinical physiology related projects resulting in research grants spanning Europe, USA and South-East Asia. Björn-Erik Erlandsson is Special Advisor, School of Technology and Health at Royal Institute of Technology in Stockholm, Sweden. He holds a M. Sc.in Electronics, Ph.D. in Applied Electronics and served as Professor of Applied Electronics at Chalmers University of Technology in Göteborg and as Co-opted professor in Biomedical Engineering at Umeå in 1991 and at Uppsala University in 2001. Björn-Erik was appointed Deputy Dean, KTH, School of Technology and Health in December 2012. He was also senior Advisor at KTH, School of Technology and Health from 2009-2012 and Senior Advisor, Stockholm County Council and K Trial Alliance, Karolinska University Hospital in 2008; served on the Uppsala County Council and Stockholm County Council from 2006-2008. He was Director of Biomed Engineering and Medical Informatics, Akademiska Hospital from 2000-2005 and Director of Biomed Medical Engineering and Informatics at the University Hospital of Northern Sweden, Umeå from 1990-2000. Professionally he was Director of QA and Reg. Affairs, AB Bofors Nobelpharma, Göteborg from 1985-1989 and Quality Mgr, Siemens-Elema AB, 1980-1985. Located in Stockholm, Alex has a background in mathematics, computer science, enterprise economics and management. As an entrepreneur he was founding partner, business development director of a joint Swedish, India BPO entity specializing in software development, 3-D graphics modeling and visualization. In this role, he personally managed large Fortune 500 global accounts. Alex is an honorary mentor for students taking the Global Entrepreneurial Leadership course, a joint course between the Royal Institute of technology, Sweden, National University of Singapore, and Stanford University. As a past Swedish junior national pole vault champion in 1998, Alex is actively involved in European athletic initiatives and sporting events providing leadership, planning and best known techniques in performance optimization. Alex has a BS and MS from the Swedish Royal Institute of Technology, KTH and is fluent in four languages Dr. Ram is an orthopedic surgeon who is currently in private practice in Yuma, Arizona and was formerly the chief of surgery at Yuma Regional Medical Center. Dr. Krishna served as chair of the Yuma Regional Medical Center Board of Trustees, president of the Yuma County Medical Society and appointed chair and secretary to the Arizona State Board of Medical Examiners by Governor’s Janet Napolitano, Jane Hull and Fife Symington. Currently, he is a member of the Arizona Orthopedic Society, Arizona Medical Association and appointed by the Arizona Medical Board to the Medical Student Scholarship Committee, University of Arizona School of Medicine. Dr. Krishna was awarded the Arizona Medical Association's Distinguished Service Award in 2000 for his exceptional work in the community. Puja has extensive breadth of experience in business development, sales and marketing, logistics and engineering. As a successful technical sales executive, Puja managed several key company accounts and generated new business in various areas of manufacturing including the semiconductor, aerospace, and medical industries. Most recently, Puja played a crucial role in successfully creating and developing the Inside Sales Team at Antares Advanced Test Technologies, a global test socket designer and supplier. Prior to Antares, Puja held roles at Intel Corporation in software and quality engineering where she successfully managed the development of media devices and chipset technology. Puja holds a degree in computer engineering from the University of Arizona Jean-Christophe is a trusted advisor to CEOs of young innovative and global companies. Jean-Christophe has 20 years of international industry experience in engineering, channel and OEM sales, strategic marketing, and venture capital management earned mostly in the Semiconductors and Communications industry. Jean-Christophe held senior business management roles at Taiwan Semiconductor Manufacturing Company and Agere Systems (AT&T Microelectronics spin-out) and he had a very successful 10-year management career at Intel Corporation and Intel Capital. He won large business deals at global communications accounts and worked extensively with the innovation ecosystem around the world. Jean-Christophe has been a Wharton Fellow since 2005; he is fluent in five languages. Brent comes to Aventyn's advisory board with a background in sales from successful start-up businesses in both the silicon and wireless space. Most recently, Brent successfully designed and spearheaded a sales strategy through strategic alliances with resellers and equipment providers for National Broadband a wireless start-up focused on providing carrier-grade broad band to rural America. Prior to this, Brent held various sales and marketing positions with Intel Corporation and Tarari, Inc. an Intel Corporation spin out. At Tarari, Inc. Brent led customer focused initiatives to design-in the industry's first hardware-based XML and Anti-Virus Content Processors developed for enterprises to secure and accelerate content processing. At Intel Corporation, Brent held group and business unit level responsibilities over the world's fastest SSL acceleration silicon. Prior to joining Intel Corporation, Brent was part of the founding team at NURON, which developed the industry's first FPGA-based SSL accelerator. NURON was acquired by Intel Corporation for $90M. Currently, Brent is a director of Sales and Business Development for ION Networks, a company that provides secure solutions for remote administration to the fortune 500. Jason comes to Aventyn with a strong corporate background and solid technical finance, portfolio, and engineering expertise. Most recently, he worked in the equity markets as a quantitative trading analyst. Prior to this role, he held various business and technical positions at Intel Corporation including senior level strategic finance supporting emerging platforms, program management of wireless networking efforts, and capacity simulation engineering. Dr. Timour Paltashev is 3D graphics architecture, processor design and SoC expert. He is well known in academic circles as a distinguished graphics professor and researcher. Timour's principal research is in 3D graphics processing units, imaging system simulation and programming interfaces for graphics accelerators. He has served as chair and advisor to GRAPHICON, SIGGRAPH, EUROGRAPHICS, editor for Computer Graphics & Geometry Internet Magazine and is a member of ACM and IEEE Computer Societies. Timour has several publications and holds multiple patents. Source: http://www.aventyn.com/
BioIntelliSense
Digital Health Innovators
The BioIntelliSense Data-as-a-Service (DaaS) platform and FDA-cleared BioSticker™ on-body sensor are bringing medical grade monitoring and management to the home for scalable remote care. An effortless user experience with a discreet and comfortable single-use design Medical grade data capture and insights with clinical accuracy physicians can trust Advanced analytics and data services for early detection Cost-effective continuous monitoring for up to 30 days on a single-use medical device Medical-grade wearable device for continuous vital sign monitoring for up to 30-days (based on configuration) Discreet, single-use disposable design for an effortless user experience Continuous temperature, respiratory rate and heart rate at rest patient trending BioMobile™ conversational AI for chronic care management and virtual care Health data protection through strict privacy and security safeguards Source: https://biointellisense.com/
Bodyport
Digital Health Innovators
Bodyport™ is a biomarker-guided digital therapeutics company addressing complex chronic conditions by delivering actionable insights gleaned from unique health signals and simple, at-home experiences. The company is tackling heart failure first with its Bodyport for Heart Health solution, to noninvasively assess heart function and fluid status at home via our Cardiac Scale, providing patients and their care teams comprehensive insights to tailor therapeutic actions and personalized insights — keeping people living with heart failure healthier and out of the hospital. Bodyport’s mission is to prevent and ultimately eliminate heart disease by empowering every person with high quality, actionable health information in their home. The Bodyport Scale detects cardiac signals through the user's feet. A familiar form factor makes daily monitoring easy, consistent, and error-free. Key cardiovascular metrics, when combined with body weight, enable a holistic health assessment rich with context. Bodyport’s care coordinators help optimize care delivery through regular monitoring and effective interventions. Source: https://bodyport.com/
Butterfly Network, Inc
Digital Health Innovators
Experience a groundbreaking ultrasound solution and the world’s only single-probe, whole-body handheld device, powered by Ultrasound-on-Chip™ technology. Butterfly transforms complex processes into one connected POCUS system to help you offer better, more efficient care. Butterfly’s mission is to democratize medical imaging by making it accessible to everyone around the world, and contribute to the aspiration of global health equity. Working to create the new image of health, Butterfly has developed a groundbreaking single-probe, whole-body point-of-care ultrasound solution leveraging its patented Ultrasound-on-Chip™ technology. Its breakthrough software solutions can integrate into hospital networks to help clinicians transform care delivery and improve efficiencies. Source: https://www.butterflynetwork.com/
CardioVisual
Digital Health Innovators
Keeping patients informed is one of the most crucial yet time-consuming aspects of being a healthcare provider, (HCP). With our patient education platform, HCPs can share clinically-vetted, in-depth educational video content with patients while saving time. CardioVisual is a health educational app that was created by US cardiologists. CardioVisual improves patient awareness with trusted information. The CardioVisual platform provides a library of 500+professionally curated videos of cardiovascular, diabetes, heart health, and wellness information that is shareable via the CardioVisual app. CardioVisual was awarded 2018 & 2019 ‘Best App for Heart Disease” by Healthline Media. Over half a million clinicians and patients in over 100 countries rely on its trustworthy interactive multimedia content. With 2-apps-in-1 for clinicians and patients, CardioVisual delivers over 500 of high-quality, clinician-curated & created videos (in English and Spanish) & infographics that provide simplified, relevant & comprehensive information about all aspects of heart & vascular disease and diabetes along with their therapies, prevention & procedures. CardioVisual is used as a trusted educational resource by clinicians (e.g. doctors, nurses, NPs, PAs, allied health professionals, etc.) in various medical settings & by patients and caregivers on their own mobile devices. It is also used by medical & nursing students and trainees, medical industry sales and clinical teams, and healthcare workers as a trusted resource. Medical and patient organizations provide this educational resource to their members. CardioVisual is regularly updated with new information & features based on active feedback from clinicians and consumers to make this a valuable informational platform, like a “Interactive Netflix of Cardiovascular and Diabetes”. CardioVisual provides accurate video explanation of conditions & treatments such as: Coronary artery disease (CAD), heart attack, angiogram, radial cath, angioplasty, stent, bypass surgery (CABG) & Cardiac Rehab Arrhythmias such as Atrial fibrillation (Afib) with Catheter RF & cryoablation, appendage occluder Heart failure & treatments, Cardiomems & VAD Stroke types, treatments including carotid stent Giving patients a credible, comprehensive resource to learn and answer questions can save clinicians’ time, improve patient satisfaction, and even improve patient compliance. MedicalVisual makes it easy to let your patients browse (or binge!) curated videos and playlists about their conditions and updated treatments on a trusted, quality platform. Every HCP has unique needs and challenges. That’s why MedicalVisual provides easy-to-use, engaging, customizable patient education solution. MedicalVisual works as a take-home or in-clinic education tool, and patients have the choice between learning at their own pace from the comfort of home or getting quick, detailed answers to questions without having to leave the clinic. MedicalVisual content is accessible by patients via laptop, tablet, or smartphone from any location and is easily integrated into a medical office through collaterals (QR posters or handouts, links, EMR codes, or iPADs/TVs) We have created free patient education sites with our most popular content. You can direct your patients to these sites to learn more about their conditions and treatments with confidence that they are seeing the most accurate, up-to-date clinical information. No registration required No limit to how many patients you can refer Multiple sites with different clinical focus Completely free to use Every healthcare provider runs a unique practice (or system) that demands a highly personalized patient education solution. Keeping your patients well-informed throughout their course of care is critical for ensuring quality outcomes, improving patient satisfaction, and encouraging compliance. Browse our available content to see what you could offer your unique patient population: VIEW DEMO Dedicated URL with your clinic’s name Your logo & color scheme on the site header Customize the top playlists shown on the site Digital tools for sharing content with patients (email & EMR messages, QR code files, etc) Physical tools for sharing content with patients (printed sheets of QR codes) Dedicated URL with your clinic’s name Your logo & color scheme on the site header Customize the top playlists shown on the site Creation of custom videos for your site (featuring your clinic’s staff) Add your existing content (or partner content) to playlists Digital tools for sharing content with patients (email & EMR messages, QR code files, etc. Physical tools for sharing content with patients, including: printed sheets of QR codes, waiting room posters, tear-off pads, and more Access to your site’s traffic and viewing data Website: https://app.cardiovisual.com/Bj7zDkRVwF Source: https://cardiovisual.com/
Carta Healthcare
Digital Health Innovators
Our industry-leading, artificial intelligence (AI)–driven technology converts both structured and unstructured healthcare data into a high-quality, reliable, standardized dataset that can be used across your organization. Accessing data in near real time from disparate systems, our products and services reduce the burden of manual data abstraction so your administrative and clinical teams can recapture that time for quality and research initiatives. Our multidisciplinary team of experts combines insights from various industries to innovate solutions to common healthcare data challenges. We are passionate about improving the healthcare environment to make the patient journey more predictable and successful. We complement our industry-leading technology with our team’s expertise to streamline workflows that have traditionally been roadblocks to hospitals efficiently harnessing their own data for patient care, quality, operational, and research initiatives. We believe that the path to a better patient journey starts with allowing nurses and physicians to once again focus on practicing and advancing medicine. Using the power of AI, Atlas frees up your staff from the tedious, manual labor of getting the data out of medical records and into clinical registries. EXPLORE ATLAS > Cartographer searches, analyzes, and interprets patient data across all platforms, standardizes those data into a consistent format, and provides the most relevant data recommendations for the task at hand. EXPLORE CARTOGRAPHER > Navigator products build on the AI capabilities of our Atlas and Cartographer solutions to mobilize your data from multiple systems and across data types. EXPLORE NAVIGATOR > Source: https://www.carta.healthcare/
Casana
Digital Health Innovators
Casana brings together a team of engineers, scientists, clinicians and business people. What unites us is an obsession with improving patient outcomes and re-inventing healthcare at home. Casana creates healthcare technologies that enable daily effortless heart health monitoring. The Casana solution is The Heart Seat™, a cloud-connected self-contained toilet seat-based cardiovascular monitoring system that measures over 9 clinical-grade metrics that have been proven through multiple peer-reviewed research studies. Using the unprecedented collection of data from The Heart Seat, Casana proactively engages with users and clinicians to provide timely information to better manage chronic disease. April 01, 2020 11:00 ET | Source: Heart Health Intelligence ROCHESTER, N.Y., April 01, 2020 (GLOBE NEWSWIRE) -- Given the current COVID-19 pandemic, the ability to monitor cardiovascular health in the home has become critical to reduce the burden on healthcare systems around the world. According to the American Heart Association, more than 80% of those over the age of 65 will have some form of cardiovascular disease (CVD) by 2035. Heart Failure, which is a chronic disease characterized by a weakened heart muscle, has a significant health and economic impact in the United States. It affects approximately 6.5 million adults and over 960,000 new cases are diagnosed each year. Heart Health Intelligence (HHI) has designed and developed The Heart Seat™, a unique cloud-connected toilet seat-based platform that effortlessly captures clinical-grade and relevant cardiac data from the patient’s home, without any change in the user’s habits. HHI has partnered with Bemis Manufacturing Company to produce The Heart SeatTM, which will transform how CVD is managed and monitored. HHI has closed its $2.2M Seed Round to support the commercialization of The Heart Seat and achieve FDA clearance. This round was led by Bemis Manufacturing Company, with additional investments from LaunchNY , RIT Venture Fund , Tech Coast Angels , Excell Partners , and Impact Capital of New York . The Heart Seat has tested its cardiac measures in over 300 subjects in partnership with University of Rochester Medical Center and the results have been published in two peer-reviewed journal articles ( 2018 and 2019 ). The Heart Seat has the potential to improve the quality of life for patients by allowing them to track health changes in the comfort of their own homes without the need to change their behavior. Khan Siddiqui, MD, HHI’s Independent Board Member, and founder of higi, stated, “Ultimately, this advancement for in-home technology will provide patients and their clinicians with information previously unavailable at an unprecedented scale. No other clinical grade technology so seamlessly integrates into everyday life.” Bemis Manufacturing Company is the largest toilet seat manufacturer in the United States that is highly innovative and has significant experience with FDA regulated devices. “We are thrilled to work with Heart Health Intelligence on this unique and impactful product that can positively impact cardiovascular health and leverages Bemis’ track record of innovation throughout its 119-year history,” stated Nan Jiang, VP of Business Development for Bemis Manufacturing Company. Nicholas Conn, PhD, HHI’s CEO, added “we are going to make a tangible difference in the lives of patients and healthcare providers. The strong partnerships we are forming now continue to add to our momentum and I’m incredibly excited for all the good that our technology has the potential do.” Heart Health Intelligence (HHI) creates healthcare technologies that enable daily effortless heart health monitoring. HHI was founded July 2018 based on research from the Rochester Institute of Technology and in partnership with the University of Rochester Medical Center. The HHI solution is The Heart Seat™ , a cloud-connected self-contained toilet seat-based cardiovascular monitoring system that measures over 9 clinical-grade metrics. Visit www.hearthealthintelligence.com . Follow us on Twitter (@hearthealthinc) and LinkedIn. Headquartered in Sheboygan Falls, Wisconsin, Bemis Manufacturing Company is a major North American molder of diverse plastic products, using engineering-grade thermoplastics and commodity resins. As a proprietary molder, Bemis is the world's largest manufacturer of toilet seats. As a custom molder, Bemis is among North America's top non-automotive producers of contract plastic injection-molded components. The company serves a host of Fortune 500 firms in consumer and industrial markets throughout North, Central and South America, and globally in Europe, Africa and the Middle East. Bemis has more than 2,000 employees worldwide. Source: https://casanacare.com/
ClearCardio
Digital Health Innovators
Your Heart Needs More Than Hope Every 40 SECONDS , someone in America has a heart attack. Every 36 SECONDS , someone dies from cardiovascular disease. Most never saw it coming because traditional tests missed the real dange The medical system has failed you. Doctors are trained to wait for blockages but blockages are the final stage of heart disease . By the time you have a 70% blockage , deadly plaque has been silently building for years. ClearCardio™ exposes what your doctor won't tell you: The $40,000 stents and invasive procedures could have been prevented. Our breakthrough AI technology detects the soft plaque deposits that rupture and cause heart attacks 10-15 years before traditional methods even know there's a problem. We don't just find heart disease, we reverse it , without surgery, without waiting, without the medical system's dangerous "wait and see" approach. Our proprietary imaging detects both calcified and soft plaque that traditional tests completely miss We measure plaque volume, density, and composition with 99.9% accuracy Every patient receives a customized action plan based on their specific plaque profile Our patients see measurable plaque reduction and risk reversal Premium, personalized care from consultation to follow-up NOTE: We do not just test for heart disease, we eliminate it. Our non-invasive, 90-minute process gives you complete clarity about your cardiovascular health and a clear roadmap to protect your future. The 'worried well' are rightly justified in their concerns. This is where ClearCardio™️ steps in—our mission is to bridge the gap between worry and wellness. By offering comprehensive cardiac assessments, including state-of-the-art cardiac CT and Cleerly™️ AI analysis, we equip you with the knowledge needed to make informed decisions about your health. Dr. John Osborne is a highly distinguished cardiologist and the founding director of State of the Heart Cardiology. He earned his B.S. with honors from Penn State University, an M.D. magna cum laude from Jefferson Medical College, and a Ph.D. in cardiovascular physiology from Thomas Jefferson University. Dr. Osborne's postdoctoral work at Harvard Medical School and Brigham and Women’s Hospital laid the groundwork for his expertise in non-invasive cardiology. Uniquely board-certified across multiple disciplines—including Cardiology, Internal Medicine, Lipidology, Clinical Hypertension, Cardiac CT Angiography, Echocardiography, and Nuclear Cardiology—his clinical focus embraces preventive cardiology, metabolic syndrome, and cardiovascular genetics. Dr. Osborne has been honored with numerous awards, such as the American Heart Association’s Cardiac Care Provider of the Year and has been recognized as a Top Doctor multiple times. His contributions to medical literature are extensive, including original research papers, book chapters, and hundreds of international presentations. Looking ahead, Dr. Osborne aims to advance the field of cardiology through ongoing research in vascular biology and genetic factors affecting heart disease. He is committed to improving patient outcomes through innovative, non-invasive treatments and continuing to influence the next generation of cardiologists through his roles in national committees and educational initiatives. He is also the founder of ClearCardio™️, an initiative dedicated to enhancing proactive cardiac care and patient empowerment through the introduction of AI technology for disease detection and treatment. JD Enright, Sr. is a seasoned business leader with over 30 years of experience collaborating with various branches of the U.S. Military, DOD divisions, and agencies such as the CIA and DIA, as well as multinational private and public sector organizations. He has co-founded several technology-based businesses and has occupied senior executive roles focusing on strategic growth initiatives in emerging markets and technologies. Enright has established himself as a key figure in identifying global technology market trends and enhancing business operations to improve financial and operational efficiencies. At ClearCardio™, he applies his extensive expertise to propel the adoption of innovative technologies such as blockchain and AI, significantly advancing the company's impact in healthcare. His leadership extends to implementing advanced high-performance computing platforms, developing blockchain-based technology strategies, advancing next-generation biotechnologies, and deploying AI for market intelligence assimilation in public healthcare applications Chief of Sales and Marketing at ClearCardio™, brings over 25 years of entrepreneurial expertise and a profound commitment to health and wellness. Initially, Sherry owned and operated several prosperous brick-and-mortar businesses before transitioning into the digital space in 2016. Here, she quickly generated over a million dollars in sales with her online nutrition and fitness programs, showcasing her skill in utilizing digital platforms for business growth. As the author of "Your Health is Non-Negotiable," Sherry has significantly influenced the field of women's health, empowering thousands with her educational initiatives. At ClearCardio™, she leverages her extensive experience to enhance the company’s visibility, develop innovative marketing strategies, and boost customer engagement. Her leadership is pivotal in driving ClearCardio™ toward new achievements in the health sector, ensuring that its services profoundly impact clients’ health journeys. At ClearCardio™ , we refuse to let you become another heart attack statistic . While other doctors wait for you to develop symptoms, we use breakthrough AI technology to detect the silent killer hiding in your arteries right now. By revealing the deadly plaque that traditional tests miss, we give you the power to prevent what kills 20 million people every year before it's too late. To stop heart attacks before they steal another life, another family, another future . Your time is running out , but it's not too late. Every day you wait, deadly plaque grows stronger in your arteries. Don't let your family plan your funeral when they could be celebrating your life . Take action now—because the next heartbeat isn't guaranteed , but your chance to save it is right here. LET US SAVE YOUR LIFE!SEE HOW NOW Home Service About Us Podcast Contact Us Source: https://clearcardio.com/
Cleerly Health
Digital Health Innovators
Cleerly goes beyond traditional measures of heart disease by performing a comprehensive assessment of each coronary artery and branch. Our AI-enabled evaluation of Coronary CT Angiography identifies, characterizes, and quantifies plaque buildup to support physicians in determining a patient's risk of a heart attack and developing a treatment plan to improve heart health. Cleerly’s technology quantifies and characterizes coronary artery disease (CAD) to help tailor therapies to a patient’s actual disease instead of indirect measures, such as surrogates, symptoms and sequelae of disease as has been done historically. Cleerly’s offerings also include innovative digital and print tools that transform complex imaging data into actionable clinical insights for clinicians and their patients. Source: https://cleerlyhealth.com/
Cliexa
Digital Health Innovators
Since our inception in 2016, the cliexa team has aimed to solve the issues within our existing healthcare system by removing the barriers that have inhibited providers from unleashing the power of patient-reported data. Cliexa does all of this by balancing a team of medical professionals and computer engineers to simplify healthcare for patients and providers. Source: https://www.cliexa.com/
CorMedica Group
Digital Health Innovators
CorMedica Group is a holding company, centered around the acquisition and growth of MedTech companies developing new and innovative AI-driven cardiovascular diagnostic technologies that align with our growing portfolio of software-as-a-service (SaaS) offerings for healthcare professionals and patients. “CorMedica’s platform provides a safe, compact, adaptable, practical and easily useable product for patients and healthcare providers.” Leo Womack, Chairman & Co-Founder Step One - Our Senior Executives are industry veterans that maintain an acquisition pipeline of companies with synergies to existing portfolio. Step Two - Acquisitions are financed with a combination of cash, earnouts and stock to ensure all parties are strategically aligned. Step Three - Companies consolidate under the CorMedica umbrella. Administrative functions, including accounting, legal, insurance and employee benefits are consolidated to allow our companies to focus on their core expertise. Step Four - New acquisitions complement existing portfolio companies and will generate revenue synergies in terms of cross selling, up selling and introducing the broader system to new customers. Available Through Non-Hostile Means – CorMedica only seeks to acquire companies whose ownership recognizes the efficiency of partnership. Consistent Financial Performance – Acquires only well-established businesses with a proven track record of success and financial stability. Highly Experienced Board and Management Team – Subject-matter experts in each of the areas and verticals the company is focused on. Strong Geographic Sales Positioning – Physical offices in key U.S. markets help leverage the global expertise of its portfolio companies with a local market presence. Diversified Revenue Mix – Balanced portfolio of evergreen recurring revenue and project-based revenue which deliver a smooth, long-term revenue stream for investors while meeting short-term revenue targets. Leo Womack , Chairman Sepand Moshiri , CEO & Co-Founder Jacinta Fitzsimons Larry W. Lawson Brad Ummer Source: https://cormedicagroup.com/
COTA - Transforming Cancer Care Through Data
Digital Health Innovators
COTA provides oncology research and development, regulatory, commercial, and HEOR teams with detailed real-world patient data to discover new treatment protocols and transform cancer care. COTA was founded in 2011 by doctors, engineers, and data scientists to create clarity from fragmented and often-inaccessible real-world data. Using technology, analytics and oncology expertise, we provide a comprehensive picture of cancer that can be used to advance care and research. We believe that everyone touched by cancer deserves a clear path to care. Together, we can make that vision a reality. Inform trial design research strategy, validate early hypotheses, make go/no-go decisions, and streamline study design with COTA’s Real-World Oncology Data Solutions. Targeting translational medicine and science teams, our dataset, featuring longitudinal data on over 2.1 million cancer patients, provides an unparalleled breadth of insight into cancer diagnoses and patient demographics. This rich resource empowers researchers to deeply understand patient outcomes, therapeutic effects, and the course of disease progression. By identifying key patterns, our data can reveal insights into disease mechanisms and open fresh perspectives for advancing drug candidates from the lab to the clinic, accelerating the journey towards Investigational New Drug (IND) applications and clinical deployment. The average cancer drug takes 10 years and $1B to develop. Streamline your process and cut out expensive, dead-end research by validating early hypotheses and using COTA data to create predictive models for treatment response so you can make faster, more informed decisions for your assets. Create optimal study designs and conditions using COTA data and clinical and statistical insights from our team of providers, statisticians, and data scientists. Real-World Evidence for Real-World Results Economically, Geographically, and Racially Diverse Over 2 Million Cancer Patient Lives in Our Database Average Length of Follow-up Between 2.6 and 10.2 years* 50/50 Academic vs. Community Treatment Setting *Depending on diagnosis Vantage is perfect for R&D teams looking to get a high-level view of a specific cancer diagnosis. Vantage provides regulatory-grade patient data that is curated for your specific use case. This data can be used for identifying trends in treatment response, uncovering outlying subpopulations, and testing hypotheses to inform future drug research. Clinicogenomics enhances our oncology database by adding comprehensive genomic profiling to real-world patient data. This add-on product reveals crucial patterns, aiding early drug discovery and development opportunities. Real-World Insights and Support is an optional, complementary add-on service that adds personalized expertise and support to your data. Our clinical and statistical experts work either as clinical advisors or as the execution arm of your team (depending on the data you choose), to provide statistical analysis and streamline study designs. R&D Teams Regulatory Teams Commercial Teams HEOR Teams Oncology Providers Focus Vantage Vista Clinicogenomics Real-World Analytics Real-World Insights & Support Our Mission Careers Become a Data Partner Source: https://cotahealthcare.com/
Deka Biosciences
Digital Health Innovators
Guided by our commitment to develop cures, we are revolutionizing cancer and inflammatory treatments. The Diakine™ platform is a next-generation cytokine therapy created to treat cancer and inflammatory disease based on each patient’s individual immune response. The different Diakines™ are composed of a disease-targeting scaffold that links together the combination of cytokines that safely stimulate the immune system to destroy cancer cells. Cytokines are naturally occurring, small proteins that control the immune system. Using single cytokines to treat cancer can be effective, but is often toxic. The Diakine™ platform combines the potent anti-cancer function of stimulatory cytokines like interleukin-2, with the inflammation-controlling function of a cytokine like interleukin-10, and targets these cytokines to the tumor, using a human single-chain variable antibody fragment. By combining the natural functions of two different cytokines, the Diakine™ platform can increase anti-cancer immunostimulatory function while reducing risk of toxic side effects – maximizing the overall potential of the immune system to fight cancer. People respond differently to various cytokine combinations. Drawing from years of research, we are now able to determine underlying cellular reactions that help us predict each patient’s immune response to different Diakines™. For cancer, we have reduced the complexities of anti-cancer immunity to an in-vitro assay that assesses the induced secretion of IFN-gamma by CD8+ T cells after exposure to each Diakine™. This test permits the evaluation of each patient’s immune response to the different combinations of cytokines, which has the potential to predict treatment response. When testing for inflammatory disease, we use a different in-vitro assay with Toll-like receptor agonists measuring stimulated monocytes secretion and response to IL-10 to determine who will potentially benefit the most from treatment with an anti-inflammatory Diakine™. Our mission is to continue to develop simple genetic tests to enable treating physicians to choose the most effective Diakine™ for each patient. Our vision is that each patient’s DiakineTM will be an optimal combination of cytokines for their genetic signature. We are developing treatments for inflammatory disease and cancer by combining precision patient selection with novel immunotherapies. We are steadfast in our mission to make these therapies effective, safe, and accessible, enabling self-administered treatment in the comfort of your home. Deka’s first clinical trial: DEKA-1 Who is this trial designed for? What is DK210 (EGFR)? Mechanism of Action (MOA) Source: https://www.dekabiosciences.com/